Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.33 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082281 | 0.81 | SMYD3 (0.43) | KDM4EALDH1A1POLBGAASLC16A3 | |
| SCHEMBL2082255 | 0.81 | TOP1 (0.47) | KDM4EALDH1A1POLBGAASLC16A3 | |
| SCHEMBL9288768 | 0.78 | SLC16A3 (0.41) | KDM4EALDH1A1POLBGAASLC16A3 | |
| SCHEMBL6621623 | 0.78 | SMYD3 (0.42) | KDM4EALDH1A1POLBGAASLC16A3 | |
| SCHEMBL2082948 | 0.78 | SMYD3 (0.38) | KDM4EALDH1A1POLBGAASLC16A3 | |
| SCHEMBL29980141 | 0.77 | SLC16A3 (0.48) | KDM4EALDH1A1POLBGAASLC16A3 | |
| SCHEMBL9735507 | 0.77 | IP6K1 (0.51) | KDM4EALDH1A1POLBGAASLC16A3 | |
| SCHEMBL501005 | 0.76 | SLC16A3 (0.38) | KDM4EALDH1A1POLBGAASLC16A3 | |
| SCHEMBL31422930 | 0.76 | IP6K1 (0.50) | KDM4EALDH1A1POLBGAASLC16A3 | |
| SCHEMBL9474864 | 0.75 | SLC16A3 (0.49) | KDM4EALDH1A1POLBGAASLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1669354-B1 | 8-CYANOQUINOLONECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-7902226-B2 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7723524-B2 | 8-cyanoquinolonecarboxylic acid derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-05-25 | — | — | US | disclosed |
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| EP-1336611-B1 | DEHALOGENO COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070123560-A1 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. | 2007-05-31 | — | — | US | disclosed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| EP-1669354-A1 | 8-CYANOQUINOLONECARBOXYLIC ACID DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1134219-B1 | CYCLOALKYL-SUBSTITUTED AMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | DAIICHI PHARMACEUTICAL CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6762181-B1 | BROAD ANTIBACTERIAL ACTIVITY INCLUDING DRUG RESISTANT STAPHYLOCOCCUS AUREUS (MRSA), PNEUMOCOCCUS (PRSP) AND ENTEROCOCCUS (VRE); SAFELY USED IN CONJUCTION WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-13 | — | — | US | disclosed |
| EP-1182202-B1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI SEIYAKU CO (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-20040063754-A1 | Dehalogeno compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1336611-A1 | DEHALOGENO COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
| US-6573260-B1 | Antibiotics | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1304329-A2 | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-1182202-A1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
| EP-1134219-A1 | CYCLOALKYL-SUBSTITUTED AMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
| EP-0807630-A1 | HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063754-A1 | Dehalogeno compounds | DEK, PGLS, RPS27L | KDM4E 2484/4885ALDH1A1 2494/4885POLB 186/4885 |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | Q6ZSR9, NAT1, NAT10 | KDM4E 744/4885ALDH1A1 861/4885POLB 2509/4885 |
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | QPCT, ASNS, C3AR1 | KDM4E 4240/4885ALDH1A1 2947/4885POLB 1682/4885 |
| US-20070123560-A1 | Dehalogeno-compounds | DEK, RPS27L, POLL | KDM4E 2618/4885ALDH1A1 3424/4885POLB 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.